Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess how glucagon administered nasally, using a nasal
dosing delivery device, works in children and adolescents compared with
commercially-available glucagon given by injection. In addition, the safety and tolerability
of glucagon given nasally was evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Eli Lilly and Company Jaeb Center for Health Research
Collaborators:
Jaeb Center for Health Research Locemia Solutions ULC